<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363189">
  <stage>Registered</stage>
  <submitdate>24/10/2012</submitdate>
  <approvaldate>26/10/2012</approvaldate>
  <actrnumber>ACTRN12612001138875</actrnumber>
  <trial_identification>
    <studytitle>Low carbohydrate diet vs carbohydrate counting in type 1 diabetes</studytitle>
    <scientifictitle>A Comparison of a Low Carbohydrate Diet vs Carbohydrate Counting on Glycaemic Control, Renal Function and Quality of Life in Type 1 Diabetes a pilot</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Type 1 Diabetes</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A low carbohydrate diet (50-75g of carbohydrate total per day patients choice of level within this range) over 12 weeks. Participants will be given information on carbohydrate amounts in foods and guidance on selecting up to 75g per day, with unlimited protein and free vegetables. Added fats will be encouraged to be limited and good choices in line with cardiocascular health advice. 8 participants will be randomised to this arm and will attend 4 group sessions to learn about the diet and matching insulin doses to this. These will be 1.5hrs once a week for the first 4 weeks of the intervention facilitated by a diabetes nurse and dietitian.</interventions>
    <comparator>Carbohydrate counting - current usual treatment over 12 weeks. 8 participants will be randomised to this arm and will attend 4 group sessions to learn about carbohydrate counting and matching insulin. This involves estimating carbohydrate content of each meal or snack and then using ratios to determine insulin dose required to match the meal. These will be 1.5hrs once a week for the first 4 weeks of the intervention facilitated by a diabetes nurse and dietitian.</comparator>
    <control>Active</control>
    <interventioncode>Lifestyle</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Glycaemic control: Glucose excursions above 8 mmol/l and below 4mmol/l over 24 hours by continuous glucose monitoring (CGMS) and glycated haemoglobin (HbA1c)</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Kidney function - Albumin creatinine ratio</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Quality of Life - audit of diabetes dependant quality of life questionnaire (AddQol)</outcome>
      <timepoint>3 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Diabetes self efficacy - using the diabetes empowerment scale (DES) questionnaire for diabetes</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Blood lipid profile</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Weight change from baseline by electronic scale</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Type 1 diabetes mellitus on a suitable insulin regime for carbohydrate and insulin manipulation</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnant or breastfeeding women
Unstable glycaemic control  HbA1c over 85</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Participants will be enrolled in the study in the order they present and randomisation envelopes will be given out consecutively</concealment>
    <sequence>Simple randomisation by using a randomisation table created by computer software (i.e., computerised sequence generation). Numbers will then be put into sealed envelopes</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/02/2013</anticipatedstartdate>
    <actualstartdate>2/04/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>24/04/2013</actualenddate>
    <samplesize>16</samplesize>
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Capital and Coast District Health Board</primarysponsorname>
    <primarysponsoraddress>Private Bag 7902
Wellington 6021</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Capital and Coast District Health Board</fundingname>
      <fundingaddress>Private Bag 7902
Wellington 6021</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Effective management of Type 1 diabetes requires matching of insulin to dietary carbohydrate in order to achieve tight glycaemic control without excessive hyper or hypoglycaemia. This can be challenging, particularly when carbohydrate intake is high or variable.  Current management focuses on providing patients with skills to estimate amounts of carbohydrate and match insulin to this.  An alternative approach is to reduce levels of dietary carbohydrate.  This is a randomised controlled trial of a low carbohydrate diet compared with the current standard carbohydrate counting treatment in 16 adults with Type 1 diabetes. Outcomes being measured include glucose excursion over 24 hours, glycaemic control, renal function and quality of life.</summary>
    <trialwebsite />
    <publication>Krebs JD, Parry-Strong A, Cresswell P, Reynolds AN, Hanna A, Haeusler S.  A randomised trial of a carbohydrate restricted diet vs standard carbohydrate counting in adults with type 1 diabetes.  Asia Pacific Journal of Clinical Nutrition 2015 (online August) doi: 10.6133/apjcn.2016.25.1.11</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Health and Disability Ethics Committee Central</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6021</ethicaddress>
      <ethicapprovaldate>22/02/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>11/12/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Amber Parry Strong</name>
      <address>Diabetes Research
Capital and Coast DHB
Private Bag 7902
Wellington 6021</address>
      <phone>+6448062458</phone>
      <fax />
      <email>amber.parry-strong@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Amber Parry Strong</name>
      <address>Diabetes Research
Capital and Coast DHB
Private Bag 7902
Wellington 6021</address>
      <phone>+6448062458</phone>
      <fax />
      <email>amber.parry-strong@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Jeremy Krebs</name>
      <address>Diabetes Research Capital and Coast DHB Private Bag 7902 Wellington 6021 </address>
      <phone>+6448062458</phone>
      <fax />
      <email>jeremy.krebs@ccdhb.org.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>